Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Transparent oil-water gels.

International journal of cosmetic science

Provost C.
PMID: 19457221
Int J Cosmet Sci. 1986 Oct;8(5):233-47. doi: 10.1111/j.1467-2494.1986.tb00453.x.

Synopsis The present article reviews both the cosmetic and the pharmaceutical literature concerning transparent oil-water gels. We propose the term 'transparent oil-water gel' for semisolid systems that consist mainly of water, oil and an emulsifying agent or agents and...

Cite
Provost C. Transparent oil-water gels. Int J Cosmet Sci. 1986;8(5):233-47doi: 10.1111/j.1467-2494.1986.tb00453.x.
Provost, C. (1986). Transparent oil-water gels. International journal of cosmetic science, 8(5), 233-47. https://doi.org/10.1111/j.1467-2494.1986.tb00453.x
Provost, C. "Transparent oil-water gels." International journal of cosmetic science vol. 8,5 (1986): 233-47. doi: https://doi.org/10.1111/j.1467-2494.1986.tb00453.x
Provost C. Transparent oil-water gels. Int J Cosmet Sci. 1986 Oct;8(5):233-47. doi: 10.1111/j.1467-2494.1986.tb00453.x. PMID: 19457221.
Copy Download .nbib Format: NLM
Pharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems.

Pharmaceutics

Mesquita L, Galante J, Nunes R, Sarmento B, das Neves J.
PMID: 30917532
Pharmaceutics. 2019 Mar 26;11(3). doi: 10.3390/pharmaceutics11030145.

Prevention strategies play a key role in the fight against HIV/AIDS. Vaginal and rectal microbicides hold great promise in tackling sexual transmission of HIV-1, but effective and safe products are yet to be approved and made available to those...

Cite
Mesquita L, Galante J, Nunes R, et al. Pharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems. Pharmaceutics. 2019;11(3)doi: 10.3390/pharmaceutics11030145.
Mesquita, L., Galante, J., Nunes, R., Sarmento, B., & das Neves, J. (2019). Pharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems. Pharmaceutics, 11(3), . https://doi.org/10.3390/pharmaceutics11030145
Mesquita, Letícia, et al. "Pharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems." Pharmaceutics vol. 11,3 (2019). doi: https://doi.org/10.3390/pharmaceutics11030145
Mesquita L, Galante J, Nunes R, Sarmento B, das Neves J. Pharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems. Pharmaceutics. 2019 Mar 26;11(3). doi: 10.3390/pharmaceutics11030145. PMID: 30917532; PMCID: PMC6472048.
Copy Download .nbib Format: NLM
An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis.

Expert opinion on drug delivery

Rahiman N, Zamani P, Badiee A, Arabi L, Alavizadeh SH, Jaafari MR.
PMID: 34747298
Expert Opin Drug Deliv. 2021 Dec;18(12):1795-1813. doi: 10.1080/17425247.2021.2003327. Epub 2022 Jan 10.

INTRODUCTION: Multiple Sclerosis (MS), as an autoimmune disease, has complicated immunopathology, which makes its management relevant to various factors. Novel pharmaceutical vehicles, especially liposomes, can support efficacious handling of this disease both in early detection and prognosis and also...

Cite
Rahiman N, Zamani P, Badiee A, et al. An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis. Expert Opin Drug Deliv. 2022;18(12):1795-1813doi: 10.1080/17425247.2021.2003327.
Rahiman, N., Zamani, P., Badiee, A., Arabi, L., Alavizadeh, S. H., & Jaafari, M. R. (2021). An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis. Expert opinion on drug delivery, 18(12), 1795-1813. https://doi.org/10.1080/17425247.2021.2003327
Rahiman, Niloufar, et al. "An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis." Expert opinion on drug delivery vol. 18,12 (2021): 1795-1813. doi: https://doi.org/10.1080/17425247.2021.2003327
Rahiman N, Zamani P, Badiee A, Arabi L, Alavizadeh SH, Jaafari MR. An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis. Expert Opin Drug Deliv. 2021 Dec;18(12):1795-1813. doi: 10.1080/17425247.2021.2003327. Epub 2022 Jan 10. PMID: 34747298.
Copy Download .nbib Format: NLM
An insight into the role of liposomal therapeutics in the reversion of Multiple Sclerosis.

Expert opinion on drug delivery

Rahiman N, Zamani P, Badiee A, Arabi L, Alavizadeh SH, Jaafari MR.
PMID: 34747298
Expert Opin Drug Deliv. 2021 Nov 08; doi: 10.1080/17425247.2021.2003327. Epub 2021 Nov 08.

INTRODUCTION: Multiple Sclerosis (MS), as an autoimmune disease, has complicated immunopathology, which makes its management relevant to various factors. Novel pharmaceutical vehicles, especially liposomes, can support efficacious handling of this disease both in early detection and prognosis and also...

Cite
Rahiman N, Zamani P, Badiee A, et al. An insight into the role of liposomal therapeutics in the reversion of Multiple Sclerosis. Expert Opin Drug Deliv. 2021;doi: 10.1080/17425247.2021.2003327.
Rahiman, N., Zamani, P., Badiee, A., Arabi, L., Alavizadeh, S. H., & Jaafari, M. R. (2021). An insight into the role of liposomal therapeutics in the reversion of Multiple Sclerosis. Expert opinion on drug delivery, . https://doi.org/10.1080/17425247.2021.2003327
Rahiman, Niloufar, et al. "An insight into the role of liposomal therapeutics in the reversion of Multiple Sclerosis." Expert opinion on drug delivery vol. (2021). doi: https://doi.org/10.1080/17425247.2021.2003327
Rahiman N, Zamani P, Badiee A, Arabi L, Alavizadeh SH, Jaafari MR. An insight into the role of liposomal therapeutics in the reversion of Multiple Sclerosis. Expert Opin Drug Deliv. 2021 Nov 08; doi: 10.1080/17425247.2021.2003327. Epub 2021 Nov 08. PMID: 34747298.
Copy Download .nbib Format: NLM
An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis.

Expert opinion on drug delivery

Rahiman N, Zamani P, Badiee A, Arabi L, Alavizadeh SH, Jaafari MR.
PMID: 34747298
Expert Opin Drug Deliv. 2022 Jan 10;1-19. doi: 10.1080/17425247.2021.2003327. Epub 2022 Jan 10.

INTRODUCTION: Multiple Sclerosis (MS), as an autoimmune disease, has complicated immunopathology, which makes its management relevant to various factors. Novel pharmaceutical vehicles, especially liposomes, can support efficacious handling of this disease both in early detection and prognosis and also...

Cite
Rahiman N, Zamani P, Badiee A, et al. An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis. Expert Opin Drug Deliv. 2022;1-19doi: 10.1080/17425247.2021.2003327.
Rahiman, N., Zamani, P., Badiee, A., Arabi, L., Alavizadeh, S. H., & Jaafari, M. R. (2022). An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis. Expert opinion on drug delivery, 1-19. https://doi.org/10.1080/17425247.2021.2003327
Rahiman, Niloufar, et al. "An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis." Expert opinion on drug delivery vol. (2022): 1-19. doi: https://doi.org/10.1080/17425247.2021.2003327
Rahiman N, Zamani P, Badiee A, Arabi L, Alavizadeh SH, Jaafari MR. An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis. Expert Opin Drug Deliv. 2022 Jan 10;1-19. doi: 10.1080/17425247.2021.2003327. Epub 2022 Jan 10. PMID: 34747298.
Copy Download .nbib Format: NLM
Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives.

Medeniyet medical journal

Siafaka P, Ipekci E, Caglar EŞ, Ustundag Okur N, Buyukkayhan D.
PMID: 34239768
Medeni Med J. 2021;36(2):152-162. doi: 10.5222/MMJ.2021.78476. Epub 2021 Jun 18.

Infants and other children can be affected by various acute, chronic and many of them rare illnesses. Developing drugs for children is very challenging since they cannot intake tablets or hard oral solid dosage forms. Besides, most of the...

Cite
Siafaka P, Ipekci E, Caglar EŞ, et al. Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives. Medeni Med J. 2021;36(2):152-162doi: 10.5222/MMJ.2021.78476.
Siafaka, P., Ipekci, E., Caglar, E. �. �., Ustundag Okur, N., & Buyukkayhan, D. (2021). Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives. Medeniyet medical journal, 36(2), 152-162. https://doi.org/10.5222/MMJ.2021.78476
Siafaka, Panoraia, et al. "Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives." Medeniyet medical journal vol. 36,2 (2021): 152-162. doi: https://doi.org/10.5222/MMJ.2021.78476
Siafaka P, Ipekci E, Caglar EŞ, Ustundag Okur N, Buyukkayhan D. Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives. Medeni Med J. 2021;36(2):152-162. doi: 10.5222/MMJ.2021.78476. Epub 2021 Jun 18. PMID: 34239768; PMCID: PMC8226405.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries